A New Generation of Anti-Viral Vaccines for Aquaculture Using Nanotechnology
Although companies based outside the U.S. have tested and, in some cases, sold basic anti-viral vaccines to aquaculture producers, practicing veterinarians and virologists have been unimpressed by their extremely limited effectiveness (J. Mullins, pers. comm. 2002; J. Winton, pers. comm. 2004). The consensus is that new approaches are urgently needed to develop viral vaccines that do not rely on DNA technology. ProFishent will apply advances in nanotechnology to the design and construction of efficacious immersion and injection vaccines to prevent mortalities from viruses and, potentially, other intracellular pathogens. Proprietary nanoparticles will be combined with model viruses (ISAV and IHNV) to create potent immunostimulatory complexes. Vaccine prototypes will be optimized and compared to traditional formulations for their ability to stimulate immunity and to protect rainbow trout and Atlantic salmon from laboratory challenges with live pathogens. Fluorescent, antigen-coated particles will also be used to observe the effect of size on uptake and transport by the immune system.
Small Business Information at Submission:
17306 NE 26th Street Redmond, WA 98052
Number of Employees: